US Top Court To Decide On Bayer's Roundup Weedkiller Appeal - Bayer (OTC:BAYZF)

The U.S. Supreme Court will likely reveal its decision over offering a clean chit to Bayer A.G.'s BAYZF Roundup weedkiller, Reuters reports.
Bayer sought the review of an appeals court that sustained $25 million in damages awarded to a user of glyphosate-based weedkiller Roundup, who blamed his cancer on the product.
Bayer urged the Court to determine federal approval of Roundup's product label by the Environmental Protection Agency as it challenged the lawsuit's viability under California's state law.
Bayer argued that the cancer claims contradict repeated product clearance from U.S. and global regulators.
Bayer prepared for up to $4.5 billion in additional litigation costs from the other claims, having coughed up a significant portion of the $11.6 billion previously allocated for settlements and litigation over the matter.
The Court is due to announce action on pending appeals on June 13.
In May, Democrat President Joe Biden urged the justices to reject the petition, unlike Republican former President Donald Trump's administration.
Bayer looks to replace glyphosate in weedkillers for non-professional gardeners in the U.S. with other active elements.
Another similar case was pending with the highest U.S. court.
Bayer remained embroiled in Roundup-related lawsuits since it acquired the brand as part of its $63 billion purchase of agricultural seeds and pesticides maker Monsanto in 2018.